STAT+: Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
An experimental medicine from Cytokinetics improved exercise capacity more than a widely prescribed beta blocker in patients newly diagnosed with a common, inherited heart condition, study results reported Saturday showed.\u00a0<\/p>\n
The Cytokinetics drug, called aficamten, is currently being reviewed by the Food and Drug Administration as a potential new treatment for obstructive hypertrophic cardiomyopathy, or HCM. If the drug is approved, the new study results could help accelerate aficamten\u2019s launch and broaden use to more HCM patients.<\/p>\n
In the Phase 3 study called MAPLE-HCM, aficamten, taken as a daily pill, showed a 1.1-point gain in peak oxygen uptake, a measure of exercise capacity, compared to a 1.2-point loss for metoprolol, a beta blocker that is commonly prescribed for newly diagnosed patients, or when they first start treatment.\u00a0<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n